Moving along faster than I expected. Word must be spreading

New Post Public Reply Private Reply Replies (0) Message Board
redspeed Mauibound #472
312
Moving along faster than I expected. Word must be spreading quickly in Israel since, not only the lead clinical site Shaare Zedek Medical Center is requesting and permitting the use of Tollovir™ in hospitalized COVID-19 patients on a compassionate use basis, but others as well.

Fact check: Covid didn't go away and the pandemic isn't over. There are 354 hospitals in Israel. The official verified number of those infected with COVID-19 is 318,291, as of today. 1,161 COVID patients are hospitalized in serious condition, with 288 on respirators. 355 are defined as critical, and 21 patients are connected to ECMO.

How many in the US?

A LOT. This is just the daily admissions with Covid

Hospitalizations_02042022.png

Is ECMO life support?
ECMO is the highest level of life support — beyond a ventilator, which pumps oxygen via a tube through the windpipe, down into the lungs. The ECMO process, in contrast, basically functions as a heart and lungs outside the body.

Yikes!

I'm not a doctor, but I'd say whatever they are treating these patients with, ain't working that well for everyone, especially the 21 on EMCO.

As more hospitals and patients in Israel receive Tollovir™, it won't take too long to find out how well it continues to work. Not being locked into a trial, they could even extend the treatment for those in the worst shape if needed I would imagine.

I've heard that compassionate use is a way to get access to experimental treatments. How does it work?

Your disease is serious or immediately life-threatening. [check]
No treatment is available or you haven't been helped by approved treatments for your disease. [check]
You aren't eligible for clinical trials of the experimental drug. [check]
Your doctor agrees that you have no other options and the experimental treatment may help you. [check]
Your doctor feels the benefit justifies the potential risks of the treatment. [check]
The company that makes the drug agrees to provide it to you. [check]

https://www.mayoclinic.org/healthy-lifestyle/...q-20058036


The crazy thing is, Tollovir™ isn't some wacky drug that you risk growing 3 more eyeballs. Other than dying because someone wouldn't let you try it, I would imagine the risk is low as shown by the data in Phase II

I did hear Gerald call Tollovir™, a Blockbuster...

Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 321

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 237

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 443

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 22

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 254

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 253

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 238

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 86

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

FCPT Expands Portfolio with $3.5 Million Veterinary Acquisition

Updated Category News Views 166

FCPT's Recent Acquisition Highlights Strategic Growth Four Corners Property Trust (NYSE:FCPT) has recently made headlines by acquiring a National Veterinary Associates property for $3.5 million. This acquisition signifies a notable addition to their expanding portfolio, reflecting FCPT's commitment to strategically investing in quality real estate. Details of the...

Continue Reading
Impact of National Security Probe on RH Stock Performance

Updated Category News Views 137

Unveiling the Impact of Recent National Security Investigations Shares of luxury furniture retailer RH have taken a significant hit due to President Donald Trump's announcement of a national security probe into furniture imports. This scrutiny has raised concerns across the home furnishings industry, known for its heavy reliance on global supply chains. Key Takeaways from...

Continue Reading
Understanding the Trends in Constellation Brands' Short Interest

Updated Category News Views 207

Exploring Constellation Brands' Short Interest Constellation Brands, identified by the ticker STZ, has recently reported an increase in its short percent of float, now at 10.22% since the last analysis. The company's latest data shows a total of 7.48 million shares sold short. This figure constitutes 4.42% of all available regular shares for trading. With an analysis...

Continue Reading
CTL's New Modular Monitor Aims to Redefine Flexibility

Updated Category News Views 7

CTL Unveils Innovative Modular Desktop Solutions CTL's latest move in the tech world features a new set of modular desktop products designed to cater to the education, enterprise, and government sectors. Their fresh offering—the CTL MTIP24OPS 24" Open Pluggable Specification (OPS)-Ready Monitor—comes along with two All-in-One computers operating on ChromeOS. This...

Continue Reading
Franklin Universal Trust Declares Monthly Share Distribution

Updated Category News Views 143

Franklin Universal Trust Announces Monthly Distribution Franklin Universal Trust [NYSE: FT] has declared a monthly distribution of $0.0425 per share, aimed at shareholders who are on record. This distribution is derived from net investment income and is set to be paid in the near future. Investment Objectives of the Fund The primary investment goal of Franklin Universal...

Continue Reading